10-QPeriod: Q1 FY2013

PFIZER INC Quarterly Report for Q1 Ended Mar 31, 2013

Filed May 10, 2013For Securities:PFE

Summary

Pfizer Inc. reported total revenues of $13.5 billion for the first quarter of 2013, a decrease of 9% compared to the same period in 2012. This decline was primarily driven by the loss of exclusivity for key products like Lipitor, leading to a significant drop in branded revenue. Despite the revenue challenges, Pfizer demonstrated strong operational execution, with income from continuing operations increasing by 60% to $2.8 billion, mainly due to favorable legal settlements and lower restructuring charges compared to the prior year. The company also made significant progress in its strategic initiatives, including the initial public offering (IPO) of its Animal Health subsidiary, Zoetis, and the sale of its Nutrition business, which are expected to streamline its portfolio and focus on core biopharmaceutical operations. The company's financial performance in Q1 2013 was marked by a significant decrease in revenues, largely due to patent expirations and generic competition impacting major products such as Lipitor. However, profitability improved substantially year-over-year, driven by reduced operating expenses, lower restructuring charges, and a favorable legal settlement. The strategic divestiture of the Nutrition business and the partial IPO of Zoetis represent key steps in Pfizer's ongoing transformation, aiming to create a more focused biopharmaceutical company. Investors should monitor the impact of ongoing product exclusivity losses and the company's ability to drive growth from its pipeline and newer products.

Financial Highlights

53 data points
Beta

Revenue

$12.41B

81.8% Gross Margin

Net Income

$2.75B

22.2% Net Margin

EPS (Diluted)

$0.38

Total Assets

$187.40B

Cash & Equivalents

$1.89B

Free Cash Flow

$2.10B

Financial Statements
Beta
Revenue$12.41B
Cost of Revenue$2.26B
Gross Profit$10.15B
SG&A Expenses$3.22B
Operating Income$2.61B
Interest Expense$371.00M
Net Income$2.75B
EPS (Basic)$0.38
EPS (Diluted)$0.38
Shares Outstanding (Basic)7.19B
Shares Outstanding (Diluted)7.27B

Key Highlights

  • 1Total revenues decreased by 9% to $13.5 billion, primarily due to product losses of exclusivity (e.g., Lipitor).
  • 2Income from continuing operations increased by 60% to $2.8 billion, driven by lower costs and favorable legal settlements.
  • 3Diluted earnings per share (EPS) increased to $0.38 from $0.24 in the prior year's quarter.
  • 4The company completed the IPO of its Animal Health subsidiary, Zoetis, selling approximately 19.8% of its shares.
  • 5Significant cost reductions were achieved through ongoing productivity initiatives and workforce reductions.
  • 6Research and Development (R&D) expenses decreased by 13% due to program discontinuations and cost savings.
  • 7The company repurchased approximately $4.6 billion of its common stock during the quarter.

Frequently Asked Questions

The primary driver of the 9% revenue decline to $13.5 billion was the loss of exclusivity for key products, most notably Lipitor, which led to significant generic competition and a substantial drop in branded revenue. Other products also contributed to this decline due to patent expirations.

Pfizer's profitability saw a significant improvement. Income from continuing operations rose by 60% to $2.8 billion, and net income attributable to Pfizer Inc. increased by 53% to $2.75 billion. This was largely due to a decrease in costs and expenses, including lower restructuring charges and a favorable change in legal matters compared to the prior year's quarter.

Pfizer made two major strategic moves: it completed the initial public offering (IPO) of its Animal Health subsidiary, Zoetis, selling approximately 19.8% of its shares, and it completed the sale of its Nutrition business to Nestlé. These actions are part of Pfizer's strategy to streamline its business and focus on its core biopharmaceutical operations.

Pfizer effectively managed its expenses, with Selling, Informational and Administrative (SI&A) expenses decreasing by 10% and Research and Development (R&D) expenses decreasing by 13%. These reductions were driven by cost-saving initiatives, workforce reductions, discontinuation of certain R&D programs, and streamlining of operations.